Search for Novartis AG and
  1. April 10, 2014

    French probe alleged drug collusion

    France’s competition authority is investigating Roche and Novartis over alleged collusion to protect one of their...

  2. April 1, 2014

    Drugmakers learn to blend commerce with philanthropy in Africa

    Africa has rarely been a source of good publicity for big pharma. But two events this week suggest the drugs industry is...

Special Reports

  1. Special Report: Boldness in Business 2012

    Seven success stories are honoured in this year’s awards...
  2. Combating Malaria 2013

    Progress runs alongside fear that an infectious disease claiming 660,000 lives a year ...
Search more Special Reports on this topic.

  1. March 18, 2014

    Hunger for long-term debt poses US rate risk

    Will it be all pain and no gain for investors who have piled into long-term corporate debt recently? Despite rising...

  2. March 10, 2014

    Novartis restructure marks break from expansion

    It is four years since Joe Jimenez took over as chief executive of Novartis. But, in some ways, it feels as if he is only...

  3. March 10, 2014

    Novartis campus wakes up sleepy home town of Basel

    In the entrance to Novartis’s research and development centre in Basel, there hangs a mosaic of 365 pieces of Iron Pyrite –...

  4. March 4, 2014

    Roche chairman fears for R&D amid squeeze on investment

    Europe risks losing investment in research and development because of the reluctance of cash-strapped governments to pay for...

  5. February 28, 2014

    Norway’s oil fund turns net seller of stocks

    Norway’s oil fund was a net seller of equities in the fourth quarter for the first time in its history even as surging share...

  6. February 16, 2014

    The Academic Week Ahead

    Monday – Feb 17 Find out about an EMBA London Business School is hosting an information session on its EMBA-Global...

  7. February 16, 2014

    Novartis puts pressure on India over patent abuse

    Novartis has urged US and European governments to “apply pressure” on India to respect intellectual property and warned New...

  8. February 13, 2014

    Recent votes call into question Swiss hospitality to business

    Few countries have been more hospitable to business than Switzerland. Its stable laws and favourable tax regime have proved...

  9. FT Alphaville

    January 29, 2014

    The (early) Lunch Wrap

    Good morning New York, FT ALPHAVILLE Cardiff looks at using reverse repo to replace the Fed Funds as the policy rate. NEWS...

  10. January 29, 2014

    Novartis considers future of $14bn Roche stake

    Novartis’s $14bn stake in its local rival Roche is one of the assets it is scrutinising as part of a broader review of its...

  11. January 9, 2014

    Novartis faces Japan probe over drug advertising

    Novartis is facing a criminal investigation of its marketing practices in Japan after the health ministry asked prosecutors...

  12. December 26, 2013

    Drug groups pin hopes on Iran market potential

    When Pfizer sold a small batch of medicines to Iran last year, the process was painful. The pharmaceutical group needed...

  13. beyondbrics

    December 13, 2013

    Novartis: looking to get flexible in Africa

    Novartis is bullish on Africa. The company’s chief executive Joseph Jimenez last week assembled his senior executives to...

  14. December 11, 2013

    J&J and Novartis mull appeal against €16m EU fines

    Johnson & Johnson and Novartis are considering whether to appeal against EU antitrust fines of €16m imposed this week for...

  15. December 8, 2013

    New Novartis chairman Jörg Reinhardt rolls back Daniel Vasella’s practices

    The man who replaced Daniel Vasella as chairman of Novartis is rolling back many of the hands-on practices of his...

  16. December 8, 2013

    Change without sour grapes

    When Jörg Reinhardt rejoined Novartis in August to take up his new role as chairman of the Swiss pharmaceutical group, he...

  17. November 24, 2013

    Swiss voters reject wage caps in referendum

    Swiss voters have decisively rejected a radical proposal that would have made it illegal for companies to pay any of their...

  18. November 22, 2013

    Novartis launches $5bn share buyback amid spending review

    Novartis’s chief executive indicated that the company’s vaccines and consumer health businesses would most likely be sold or...

  19. November 20, 2013

    Outlawing high pay will cost Switzerland dear

    Executive pay is a tense subject in many places but the Swiss are the first to raise it to the status of a formal national...

  20. November 19, 2013

    Big drugmakers such as Novartis turn from expansion to divestment

    When Novartis revealed the sale of its blood diagnostics business last week, investment bankers could lick their lips at the...

  21. November 11, 2013

    Proposals to shake up Norway’s oil fund

    Norway’s $800bn oil fund would undergo its biggest organisational change in a decade under proposals from a...

  22. FT Alphaville

    November 11, 2013

    The (early) Lunch Wrap

    Good morning New York, FT ALPHAVILLEWith the stock market seemingly unsure of whether more jobs are good or bad, Dan has a...

  23. November 11, 2013

    Novartis agrees $1.7bn sale of blood diagnostics unit to Grifols

    Novartis has agreed to sell its blood diagnostics unit to the Spanish healthcare group Grifols for $1.7bn, in the first of a...

  24. November 10, 2013

    Shire delivers fresh blow to UK life sciences

    As chief executive of Shire, Flemming Ornskov has to spend time in the UK talking to investors and employees, but he is just...

  25. November 8, 2013

    Bristol-Myers Squibb could realise $6bn from diabetes franchise

    Bristol-Myers Squibb could generate up to $6bn from the sale of its diabetes franchise, according to an analyst’s projection...

  26. November 6, 2013

    Shire set to axe dozens of research jobs

    Shire, the Irish-domiciled pharmaceuticals group, is poised to announce a restructuring programme to include the loss of...

  27. October 22, 2013

    Novartis shake-up fuels talk of $4bn animal health disposal

    Novartis has rejigged its executive board, triggering speculation that the Swiss pharmaceuticals group could be preparing to...

  28. October 17, 2013

    Roche / Novartis: combination therapy

    Winter might be descending on the Alps, but spring is in the air in Basel. The Swiss city, home to Roche and Novartis, has...

  29. October 11, 2013

    Drug research: caring and sharing

    Which is more important – curing cancer, or malaria? Either will cost a fortune, take a long time to develop and benefit...

  30. September 30, 2013

    Roche chief Severin Schwan open to co-operation with Novartis

    Roche’s chief executive has signalled openness to renewed co-operation with counterparts at his Swiss rival Novartis, in a...

  31. September 30, 2013

    Europe belt tightening will hit pharma, warns Roche chief

    Europe risks squandering its leading position in the global pharmaceuticals industry because of the “short-term” and...

  32. FT Data

    September 24, 2013

    China's pharmaceutical market: risks and opportunities

    The media furore surrounding Beijing’s probes into corruption by drug companies has drawn attention to the nature of China’s...

  33. September 23, 2013

    Bribery claims infect drug companies’ dealings in China

    It began as a rumour on a Chinese social media site in July, but the impact has swiftly spread around the world: allegations...

  34. September 17, 2013

    Novartis’s Alcon embroiled in Chinese corruption allegations

    Alcon, the eyecare division of Novartis, said it would investigate claims it used fake clinical trials to bribe doctors in...

  35. September 3, 2013

    BioMérieux buys privately held BioFire for $450m

    BioMérieux, the quoted French diagnostics company, is to pay $450m to buy a US rival in a deal designed to reinforce and...

  36. August 25, 2013

    Reticent Daniel Vasella remains proud of legacy and record at Novartis

    For a man with outspoken views, Daniel Vasella has been curiously quiet during the past six months, since he announced his...

  37. August 25, 2013

    Amgen’s $10.5bn takeover of Onyx approved by both boards

    Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

  38. August 25, 2013

    Former Novartis chairman Daniel Vasella defends $78m pay-off

    Daniel Vasella, the outgoing head of Novartis, has defended his proposed $78m farewell package from the Swiss drugs group,...

Search for Novartis AG and

RELATED VIDEOS

Videos from FT.com that closely match this topic

  1. Lex on potential conflict at Swiss drugs group...
    July 17, 2013

    Lex on potential conflict at Swiss drugs group

  2. Lex on Novartis' payment to its outgoing chairman...
    February 18, 2013

    Lex on Novartis' payment to its outgoing chairman